Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PolyICLC

Other

Phase 1/2 Most advanced trial (none active)
1 Registered trials

What is PolyICLC?

PolyICLC is a synthetic double-stranded RNA compound. It is studied in melanoma, including uveal melanoma and ocular melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
In trials of
CLDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04364230 Phase 1/2 Melanoma Completed CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

MelanomaOcular MelanomaUveal Melanoma

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.